GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alkermes PLC (NAS:ALKS) » Definitions » PB Ratio

Alkermes (Alkermes) PB Ratio

: 3.31 (As of Today)
View and export this data going back to 1991. Start your Free Trial

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-04-20), Alkermes's share price is $23.86. Alkermes's Book Value per Share for the quarter that ended in Dec. 2023 was $7.20. Hence, Alkermes's PB Ratio of today is 3.31.

The historical rank and industry rank for Alkermes's PB Ratio or its related term are showing as below:

ALKS' s PB Ratio Range Over the Past 10 Years
Min: 1.81   Med: 4.21   Max: 8.46
Current: 3.31

During the past 13 years, Alkermes's highest PB Ratio was 8.46. The lowest was 1.81. And the median was 4.21.

ALKS's PB Ratio is ranked worse than
73.47% of 961 companies
in the Drug Manufacturers industry
Industry Median: 1.9 vs ALKS: 3.31

During the past 12 months, Alkermes's average Book Value Per Share Growth Rate was 13.40% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 2.40% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -1.20% per year. During the past 10 years, the average Book Value Per Share Growth Rate was -2.40% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Alkermes was 314.20% per year. The lowest was -69.30% per year. And the median was 3.70% per year.

Back to Basics: PB Ratio


Alkermes PB Ratio Historical Data

The historical data trend for Alkermes's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alkermes Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.76 2.77 3.15 3.83 3.85

Alkermes Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PB Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.83 4.33 3.78 3.20 3.85

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Alkermes's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alkermes PB Ratio Distribution

For the Drug Manufacturers industry and Healthcare sector, Alkermes's PB Ratio distribution charts can be found below:

* The bar in red indicates where Alkermes's PB Ratio falls into.



Alkermes PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Alkermes's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=23.86/7.203
=3.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Alkermes  (NAS:ALKS) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Alkermes PB Ratio Related Terms

Thank you for viewing the detailed overview of Alkermes's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Alkermes (Alkermes) Business Description

Traded in Other Exchanges
Address
1 Burlington Road, Connaught House, Dublin, IRL, D04 C5Y6
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several collaborative arrangements to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies.
Executives
Cato T Laurencin director C/O UNIVERSITY OF CONNECTICUT, 263 FARMINGTON AVENUE, FARMINGTON CT 06030-3800
Christian Todd Nichols officer: SVP, Chief Commercial Officer 852 WINTER STREET, WALTHAM MA 02451
Nancy Wysenski director 2200 SUNBURST STREET, CHATSWORTH CA 90401
Daglio David Angelo Jr. director ALKERMES, 852 WINTER STREET, WALTHAM MA 02451
Christopher I Wright director C/O CYCLERION THERAPEUTICS, INC., 245 FIRST STREET, 18TH FLOOR, CAMBRIDGE MA 02142
Michael J Landine officer: SVP, Corp Dev., Alkermes, Inc. 88 SIDNEY ST, CAMBRIDGE MA 021394136
Richard F Pops director, officer: Director and CEO, Alkermes plc 10555 SCIENCE CENTER DR, SAN DIEGO CA 92121
Shane Cooke officer: President, Alkermes plc TREASURY BUILDING LOWER GRAND CANAL ST., DUBLIN 2 L2 00000
Blair Curtis Jackson officer: EVP, Chief Operating Officer 852 WINTER STREET, WALTHAM MA 02451
Snyderman Nancy Lynn Md director 37 PHEASANT HILL ROAD, PRINCETON NJ 08540
Craig C. Hopkinson officer: SVP, Med Dev/Med Affairs, CMO 852 WINTER STREET, WALTHAM MA 02451
Emily Peterson Alva director C/O AMNEAL PHARMACEUTICALS LLC, 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
Iain Michael Brown officer: VP, Finance & CAO 14 ROYALSTON AVENUE, WINCHESTER MA 01890
Brian P Mckeon director IDEXX LABORATORIES, ONE IDEXX DRIVE, WESTBROOK ME 04092
David Joseph Gaffin officer: SVP, CLO, Alkermes, Inc. 852 WINTER STREET, WALTHAM MA 02451